ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

Impact · against what's priced in

ONWARD Medical's Q3 2026 revenue of EUR 2.5M establishes a baseline annualized run rate of EUR 10M. While the results demonstrate commercial momentum, the impact is modest as it provides a concrete starting point for valuation rather than a surprise shift in fundamentals.

Scored by the NIS engine · methodology.

ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

earnings
healthcare
medical devices
neurotechnology

ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

What matters in this story

How each ticker is affected

Biomérieux third-quarter sales grew more than expected

ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

What matters in this story

How each ticker is affected

Biomérieux third-quarter sales grew more than expected

Track these names every morning.

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Apple stock sinks despite record earnings as a new threat hits its margins

ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

What matters in this story

How each ticker is affected

Next reads from the same story arc

Biomérieux third-quarter sales grew more than expected

ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

What matters in this story

How each ticker is affected

Next reads from the same story arc

Biomérieux third-quarter sales grew more than expected

Track these names every morning.

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Apple stock sinks despite record earnings as a new threat hits its margins